Eyal Shamir - Icecure Medical CEO Director
| ICCM Stock | USD 0.83 0.04 5.34% |
Insider
Eyal Shamir is CEO Director of Icecure Medical
| Age | 63 |
| Address | 7 Ha?Eshel Street, Caesarea, Israel, 3079504 |
| Phone | 972 4 623 0333 |
| Web | https://www.icecure-medical.com |
Icecure Medical Management Efficiency
The company has return on total asset (ROA) of (0.4736) % which means that it has lost $0.4736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9422) %, meaning that it created substantial loss on money invested by shareholders. Icecure Medical's management efficiency ratios could be used to measure how well Icecure Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.94. In addition to that, Return On Capital Employed is likely to drop to -1.3. At this time, Icecure Medical's Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Non Currrent Assets Other is likely to grow to about 67.8 K, while Total Current Assets are likely to drop about 11.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Ordway | Sight Sciences | N/A | |
| Paul Talmo | Tela Bio | 52 | |
| Margaret Carthy | Integer Holdings Corp | 60 | |
| Christopher Smith | Tela Bio | 63 | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| Andre Marquette | Neuropace | N/A | |
| Danilo DAlessandro | Clearpoint Neuro | 38 | |
| Mark Saxton | Neuropace | 59 | |
| Peter Murphy | Tela Bio | 51 | |
| MS MS | Cytosorbents Crp | 66 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Gina Moss | SINTX Technologies | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Mazin Sabra | Clearpoint Neuro | 43 | |
| Moria Ankri | Brainsway | 40 | |
| Christopher Lesovitz | STRATA Skin Sciences | 41 | |
| Jeremy Hayden | Sight Sciences | 54 | |
| Christopher Boyer | BrainsWay | 45 | |
| Richard Ginn | Tenon Medical | 58 | |
| Moria Ankri | BrainsWay | 39 | |
Management Performance
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.47 |
Icecure Medical Leadership Team
Elected by the shareholders, the Icecure Medical's board of directors comprises two types of representatives: Icecure Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icecure. The board's role is to monitor Icecure Medical's management team and ensure that shareholders' interests are well served. Icecure Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icecure Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Naum Muchnik, Dev Research | ||
| Eyal Shamir, CEO Director | ||
| Galit Malik, Vice Service | ||
| Shay Levav, VP Applications | ||
| Ronen CPA, CFO COO | ||
| Merav Dotan, Vice Resources | ||
| Tlalit TelTzure, Vice Marketing |
Icecure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icecure Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (3.19) % | ||||
| Current Valuation | 33.71 M | ||||
| Shares Outstanding | 55.5 M | ||||
| Shares Owned By Insiders | 54.17 % | ||||
| Shares Owned By Institutions | 0.39 % | ||||
| Number Of Shares Shorted | 282.23 K | ||||
| Price To Book | 4.11 X | ||||
| Price To Sales | 13.08 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Icecure Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Icecure Stock, please use our How to Invest in Icecure Medical guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icecure Medical. If investors know Icecure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icecure Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 0.071 | Quarterly Revenue Growth 0.079 | Return On Assets (0.47) | Return On Equity (0.94) |
The market value of Icecure Medical is measured differently than its book value, which is the value of Icecure that is recorded on the company's balance sheet. Investors also form their own opinion of Icecure Medical's value that differs from its market value or its book value, called intrinsic value, which is Icecure Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icecure Medical's market value can be influenced by many factors that don't directly affect Icecure Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icecure Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icecure Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icecure Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.